VYN201 Produces Positive Biomarker Changes in Vitiligo
VYN201 demonstrated a positive effect on key biomarkers relevant to nonsegmental vitiligo, according to new data from a Phase 1b Trial. VYNE Therapeutics Inc.’s VYN201 is a pan-bromodomain BET inhibitor designed to be locally administered to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. BET inhibitors have the potential to […]